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Introduction: Atrial fibrillation is a common cardiac arrhythmia and a major cause of 
ischaemic stroke. Stroke risk can be accessed using scores like CHA2DS2VASc and 
thromboprophylatic therapy with oral anticoagulants might be indicated, whose efficacy is 
well proven. However it’s also linked to a risk of haemorrhage that cannot be neglected. 
Considering that thrombus formation is mainly linked to left atrial appendage, other non-
pharmacological alternatives are being developed, as local therapies. However, evidence and 
experience about these approaches are lacking from patients with concomitant hepatic 
disease, making the decision on how and when to start therapy very delicate and stressful. 
Methodology: we conducted a research using data sources like Medline Ovid (until January 
2018) and the Cochrane Central Registry. We presented our results from the selected articles 
in tables. Then we analysed our information and built an algorithm.  
Results: Traditional anticoagulant therapy and NOACs seem to be safe in patients with mild 
or moderate hepatic impairment, except for rivaroxaban and edoxaban, whose use is not 
advised for patients with moderate impairment. Nonetheless, patients should undergo regular 
monitoring of drug levels and hepatic enzymes. The LAAC techniques are several and one 
proved to be at least non-inferior to warfarin in a large randomized controlled trial. 
Conclusions: More studies are required to proof OAC’s efficacy and safety in patients with 
chronic hepatic disease (CHD), in order to build a  guideline for clinicians. The left atrial 
appendage occlusion has revealed promising results but no study was yet conducted in 
patients with CHD. Anticoagulant therapy remains the first line for thromboprophylaxis, 
being LAAC reserved for patients with declared contraindications to OAC. 
Keywords: Atrial Fibrillation control, Chronic Hepatic Disease, Stroke/TIA Prevention, 
Bleeding complications, Therapy. 
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Introdução: A fibrilhação auricular é uma arritmia frequente e uma causa major de AVC 
isquémico. O risco de AVC é avaliado através de scores como CHADS2 ou CHA2DS2VASc, 
podendo indicar o inicio de terapêutica trombo-profilática. A profilaxia do AVC com 
anticoagulantes orais tem uma eficácia conhecida, porém associada a um risco de hemorragia 
que não deve ser ignorado. Considerando que a formação de trombos está maioritariamente 
associada à aurícula esquerda, outras técnicas não farmacológicas estão a ser desenvolvidas 
de forma local. No caso do paciente também sofrer de doença hepática crónica, a eficácia e 
a segurança destas abordagens não está ainda esclarecida, sendo a escolha de como e quando 
começar terapêutica ainda difícil, considerando a pouca evidencia disponível.   
Métodos: Realizámos uma pesquisa em bases de dados como Medline Ovid (até janeiro de 
2018) e a Cochrane Central Registry. Dos artigos selecionados apresentámos os nossos 
resultados em tabelas e analisámos o seu conteúdo. Finalmente elaborámos um algoritmo. 
Resultados: A terapêutica anticoagulante oral tradicional e os novos anticoagulantes orais 
parecem ser seguros para doentes com doença hepática ligeira e moderada, exceto o 
rivaroxaban e o edoxaban, cujo uso não está indicado em casos de doença moderada; os 
doentes devem sujeitar-se a controlos regulares dos níveis dos fármacos e das enzimas 
hepáticas. As técnicas de encerramento da aurícula esquerda são diversas e uma delas 
provou, num ensaio controlado e randomizado, ser não inferior à varfarina.  
Conclusões: Mais estudos devem ser realizados a fim de provar a eficácia e a segurança do 
uso de anticoagulantes em pacientes com doença hepática crónica com o fim de obter uma 
norma orientadora para a clínica. A oclusão da aurícula esquerda tem-se revelado 
promissora, porém nenhum estudo foi realizado especificamente em pacientes com cirrose, 
permanecendo a terapêutica anticoagulante como primeira linha. A alternativa local fica 
reservada aos doentes cuja anticoagulação está contraindicada. 
Palavras-chave: Fibrilhação Auricular, Doença Hepática Crónica, prevenção de AVC/TIA, 
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1 | Introduction 
Atrial fibrillation (AF) is a frequent cardiac arrhythmia, affecting 0.1 % of adults with 
less than 55 years and 9.0% of persons aged 80 years or older[1], representing non-valvular 
AF alone, a five-fold increase in stroke risk[2]. In this condition, the atria activate in a chaotic 
pattern, leading to an ineffective atrial contraction, propelling thrombus formation and 
representing a risk factor for thromboembolic events such as stroke. This risk can be assed 
using the different scales or scores developed by clinicians (CHADS2, ATRIA, 
HEMORR2HAGES…), and the scores CHA2DS2VASc (more sensitive to low-risk patients 
stratification than the older CHA2DS2[2]) and HAS-BLED  reunite the biggest consensus 
among clinicians and investigators[3]. In both cases a high score corresponds to a greater risk 
of ischaemia or bleeding, respectively, and vice-versa.  
The scores take into account multiple risk factors from the patient’s profile. The 
CHA2DS2VASc score (heart failure, hypertension, age 65-74, age ≥ 75, diabetes mellitus, 
stroke or transient ischemic attack, vascular disease, female sex) is used to stratify stroke 
risk in patients with non-valvular atrial fibrillation into risk categories, identifying the 
patients who would benefit from prophylactic treatment or not. According to the latest 
guidelines from AHA 2014 should be initiated when the score is more than 2 and for the 
ESC 2016 when the score is more than 1 in men and more than 2 in woman[3, 4]. In the other 
and, the HAS-BLED score (hypertension, renal disease, liver disease, stroke or transient 
ischaemic attack, prior major bleeding or predisposition to bleeding, labile INR, age > 65, 
medication predisposing to bleeding, alcohol use), also recommended in the most recent 
guidelines, is important to access the risk of major bleeding events in patients with AF taking 
oral anticoagulants. This global categorization is helpful for shaping the patient’s monitoring 
scheme, especially in high risk cases, where more frequent patient-doctor visits should be 
encouraged.  
The incidence of AF is higher in patients with non-alcoholic fatty liver disease 
(NAFLD), the most frequent chronic liver disease worldwide, with up to 40% of NAFLD 
cases progressing to fatty liver cirrhosis in 10 years[5]. Also, atrial fibrillation and liver 
disease might share pathophysiological paths, as described by Ya-Hui Ding and his team[6]. 
Chronic liver disease (CLD) has long been an important obstacle to the use of oral 
anticoagulants, even now that its applicability and benefits are well described[7, 8]. The reason 
is most probably related to the bleeding risk associated to oral anticoagulant (OAC) therapy, 
and to the fear of using it in a group of patients who are considered to be already at a bigger 
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risk for haemorrhage than the general population. This idea might have limited the inclusion 
of these patients in some studies about OAC’s efficacy and safety.  
Indeed, coagulopathy represents a challenge in the follow-up of these patients. The liver 
is the one responsible for the production of pro-coagulant and anti-coagulant factors 
involved in the haemostatic system and when the liver is damaged, the parenchyma suffers 
a reduction in the number of hepatocytes and the liver blood flow is also decreased. 
Eventually, the synthesis of factors involved in the coagulation cascade and the hepatic 
metabolism are altered, with decreased levels of the factors II, V, VII, IX, X, XI and also on 
the levels of protein C, protein S or plasminogen[9, 10], along with a decreased production of 
platelets with an altered function. Contrarily to earlier beliefs, both haemorrhagic and 
thrombotic complications might emerge, which motivated clinicians to speak about a new 
rebalanced haemostasis, where a more fragile equilibrium is obtained[11–13]. Tripodi A. et al 
studied the role of platelets in the generation of thrombin and they proved that cirrhosis does 
not affect platelets pro-coagulant activity but if they are in low concentration (<60x109/L) 
the production of thrombin may be diminished, correlating thrombocytopenia, frequently 
found in CHD, with bleeding tendencies.  
Further, haemorrhage is currently analysed as an independent risk factor in the decision 
making process on who, when and how to start anticoagulant treatment. For the bleeding 
risk assessment, HAS-BLED is the most commonly used score, which predicts bleeding 
events associated to oral anticoagulant therapy and includes liver disease has a risk factor. A 
score of ≥ 3 indicates ‘high risk’ of bleeding [3]. 
Along with the already described manifestations of chronic hepatic disease there’s also 
oedema, ascites, oesophageal varices, hepatic encephalopathy and, in the case of advanced 
cirrhosis, the hepatorenal syndrome, lined with altered renal function, demanding frequent 
dosage monitoring and adjustments when using drugs with renal excretion. Several studies 
were conducted on this subject, in order to understand the effect of renal dysfunction on oral 
anticoagulant’s metabolism[14, 15] but almost none pondered about the effect of hepatic 
impairment on the pharmacodynamics and pharmacokinetics of OACs.  
Mechanisms related to the hepatic impairment and the drugs own pharmacological 
characteristics are responsible for the changes in their effects, and emergent data is needed 
to well document and predict these drugs behaviour under these circumstances. To access 
the level of hepatic impairment, the Child-Turcotte-Pugh (CTP) score is the most widely 
used system (Combines the symptoms ascites and encephalopathy with 2 laboratory 
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parameters, serum albumin, serum bilirubin and prothrombin time), and the MELD score 
(Model of end-stage Liver Disease) is a simple tool that helps to predict the patient’s 
prognosis.  Both of them offer no help on eventual dose adjustments of OAC therapy 
according to liver function, because they lack the sensitivity to quantify the specific ability 
of the liver to metabolise individual drugs or predict pharmacodynamics effects.  
Even thought there are still no current guidelines on how to manage thrombotic 
complications in patients suffering from chronic hepatic disease, it has been well established 
that anticoagulant treatment should not be withheld from patients with cirrhosis even if their 
profile represents a higher bleeding risk when combined with OAC therapy[4]. 
The relevance of this subject is obvious as the prevalence of AF is presumed to increase 
in the coming years[16][17] supporting an eventual increase in the incidence of stroke, making 
it’s prevention a major priority. Another important consideration is that its sequelae also tend 
to be worse when derived from atrial fibrillation compared to other ethyologies[18].  
In AF patients, thromboprophylaxis has been demonstrated to be non-inferior or 
superior when performed with NOACs in comparison to vitamin k antagonists (VKA) with 
lower rates of haemorrhagic stroke or other bleeding complications[19–22]. Also, NOAC 
present many desirable features such as low food and drug interactions, quick onset of action 
and no need for regular monitoring. Despite the known advantages of the direct oral 
anticoagulants, experience is still lacking in some “special” groups.  
Interestingly, there are other non-pharmacological approaches already approved in the 
most recent guidelines for stroke prevention in a selective group of patients with atrial 
fibrillation[3, 4], where left atrial appendage closure (LAAC) assumes an important role and 
received a class IIb recommendation in patients unsuitable for OAC therapy. These 
approaches are presently receiving a special attention from the scientific community for its 
possibilities in patients for whom the use of pharmacological therapies for a long-term of 
time is considered contraindicated. 
Unfortunately, most of the randomized controlled trials that compared some of the 
different alternatives, excluded patients with hepatic impairment and a direct comparison 
between the different methods is still non-existent, leaving physicians with no guidelines 
available to support their work when managing treatment or prevention of thrombotic events 





The aim of this study was to collect and present data about the safety and efficacy of 
the different approaches available to prevent stroke in patients suffering from both atrial 
fibrillation and chronic hepatic disease. We only discussed therapeutic options that are 
























Figure 1 – methodology algorithm 
 
Information sources 
Between September 2017 and April 2018, we conducted a research in Medline Ovid and 
umtil January 2018 in the Cochrane Central Register, using the following terms: atrial 
fibrillation, chronic hepatic disease, stroke, warfarin, noac, rivaroxaban, apixaban, 
edoxaban, dabigatran, left atrial appendage, bleeding. We conducted then a selection of the 
elegible studies and did a further scan to the articles we read fully, collecting others in their 
bibliography.  
Study selection and eligibility criteria 
In total, 2166 records were identified from the specified databases. The two 
investigators independently screened all titles and abstracts. We selected 41 articles for full 
reading and examination, plus the articles collected from the bibliography, and then we 
created a table of contents and further analysed if they met the criteria to be included in this 
review. Our inclusion criteria were as follows: studies of patients with atrial fibrillation in 
whom the prevention of stroke is being analysed; the patients have contraindications to 
anticoagulant therapy or suffer from chronic hepatic disease; the studies mention the use of 
novel oral anticoagulants, warfarin or left atrial appendage.  
 observational 
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Given the relatively few studies in populations with chronic hepatic disease, we decided 
to analyse not only control trials, but also cohorts and registries in populations with 
contraindications to oral anticoagulant therapy. We excluded trials if they didn’t met the 
eligibility criteria or had no outcomes of interest. 
Any disagreements between the two reviewers regarding the eligibility or relevance of 
specific articles were discussed between them.  
We resumed in tables the collected information about the different approaches available 
and analysed it considering the primary efficacy and safety outcomes. Finally we present our 




3 | Collected data and Clinical Evidence 
 
Oral anticoagulants for stroke prevention in patients with CHD  
The efficacy of anticoagulation in reducing the risk of systemic embolization in patients 
with AF is well established, with an estimated risk reduction in ischaemic stroke events of 
around 64% - an absolute annual risk reduction of 2.7% in all strokes[31]. For years, warfarin 
was the most commonly applied therapy for this purpose, with convenient advantages like 
oral administration and low price. 
Effect of hepatic impairment on the Novel Oral Anticoagulants 
in vitro studies 
STUDY NAME POPULATION INTERVENTION RESULTS  
Potze W, Arshad 
F. et al.[9] 
Patients with CTP A 
(n=10), CTP B 
(n=10), CTP C 
(n=10) and controls 
(n=30) 
Added 25 ng/mL of 
rivaroxaban 
 to plasma samples 
Dabigatran caused a more pronounced reduction in 
thrombin generation in patients vs. controls (72.6% in 
patients vs. 12.8% in controls, P<0.01). 
Added 300ng/ml of 
dabigatran to plasma 
samples 
Rivaroxaban caused a less pronounced decrease in 
thrombin generation in patients vs. controls  (39.3% in 
patients vs. 54.5% in controls P<0.01) 
Potze W, 
Adelmeijer J. et 
al.[32] 
Patients with CTP B 
(n=9), CTP C (n=5) 
and 11 healthy 
individuals 
Added 25 ng/mL of 
apixaban to plasma 
samples 
Apixaban lead to a lower decrease in thrombin 
generation in patients vs. controls (32% in patients vs. 
51% in controls, P<0.0001) 
  Added 50 ng/mL of 
rivaroxaban to plasma 
samples 
Rivaroxaban caused a lower decrease in thrombin  
generation in patients vs. controls (30% in patients vs. 
55%  in controls, P<0.0001) 
In vivo studies  
STUDY NAME POPULATION INTERVENTION RESULTS 
Kubitza et al.[33] 
Patients with CTP 
A (n=8), CTP B 
(n=9) and matched 
healthy controls 
single oral dose of 
10 mg of rivaroxaban 
after 10h fasting 
period 
- Subjects with mild hepatic impairment had similar 
inhibition of Factor Xa activity vs. controls, and 
similar PT prolongation.  
- Subjects with moderate hepatic impairment 
experienced an increased and more sustained 
inhibition of Factor Xa activity (28% after 24 h in 
subjects with moderate hepatic impairment vs. 4% in 
healthy subjects), and PT prolongation was more 
pronounced in subjects with  moderate hepatic 
impairment (2.14-fold). 
Stangier et al.[34] 
Patients with CTP B 
(n=12) and matched 
healthy controls 
single oral dose of 150 
mg of dabigatran 
etexilate 
- Mean half-life (11.5 controls vs. 11.8 in patients) and 
clearance period (65.2mL/min in controls vs. 
63.1mL/min in patients) of dabigatran were similar 
between groups.  
- Median tmax of dabigatran was achieved 2 hours 
after drug administration in both groups. 
- Ratios of the area under the concentration-time curve 
(AUC) and Cmax in controls vs. patients showed an 
average 5.6% decrease of AUC (94.4; 90% CI, 52.2-
171) and 30% (70.2%; 90% CI, 38.5%-128%); Cmax 
was lower in patients with hepatic impairment (76.1 
ng/mL vs with 107 ng/mL in controls); 
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Table 1 – The effect of hepatic impairment on NOACs in vitro and in vivo. 
 
In a real life context, even after AF is diagnosed and the risk for stroke is identified, 
only a percentage of patients receives anticoagulant treatment and only 50% keeps taking it 
after 3 years of initiating treatment[37, 38]. Moreover, the patients often have an INR outside 
of the therapeutic range, and the need for regular monitoring and frequent dose adjustments 
end up being the biggest disadvantages of VKAs in what concerns the patient’s adherence 
to therapy. To note that the efficacy and safety of VKAs are dependent on the quality of their 
management, where an INR below the reference represents a risk for thrombosis and an INR 
above increases the risk of bleeding[39]. This interpretation is very difficult in patients with 
cirrhosis due to it’s impact on coagulation and clotting system. In spite of that, the biggest 
influencer in therapy dropouts are bleeding tendencies, the main side effect of OAC therapy. 
Until 2008, Vitamin K antagonists were the only drugs approved for stroke prophylaxis, 
when the novel oral anticoagulants emerged and brought new possibilities to the clinicians. 
NOACs have a more predictable pharmacokinetic profile, exhibiting their effect by directly 
inhibiting a single factor in the coagulation cascade. They’re administered at fixed doses and 
- Baseline PT time was prolonged in patients with 
hepatic impairment vs. controls (INR was 1.40 in 
patients vs. 1.02 in controls). Baseline activated partial 
thromboplastin clotting time (aPTT), ecarin clotting 
time (ECT), thrombin time (TT) were unchanged. 
Frost et al.[35] 
Patients with CTP A 
(n=8) or B (n=8)  
and matched healthy 
controls 
single oral dose of 5 
mg of apixaban + 
lidocaine 1mg/kg 4 
days later 
- Area under the concentration-time curve point 
estimates and 90%CI were 1.03 (0.798, 1.32) for mild 
impairment and 1.09 (0.849, 1.41) for moderate 
hepatic impairment vs. controls. 
- Protein binding was 93%, 93% and 92% for controls, 
mild impairment and moderate impairment groups, 
respectively.  
- Baseline INR was higher in patients vs. controls, but 
percentage changes from baseline were similar across 
groups.  
Mendell et al.[36] 
Patients with CTP A 
(n=8), CTP B (n=9) 
and matched healthy 
controls 
single 15mg dose of 
edoxaban to every 
patient 
- Mean baseline PT values were elevated in subjects 
with mild (12.3 seconds) or moderate (13.3 seconds) 
hepatic impairment compared with their respective 
controls (11.3 and 11.0 seconds).  
- Cmax of edoxaban was similar between subjects with 
mild impairment vs. controls; but the median tmax was 
2 times higher for the moderate hepatic impairment 
cohort vs. controls.  
- t 1/2 of edoxaban was longer for subjects with hepatic 
impairment, (1 hour increase for mild and 1.4 hours for 
moderate) vs. controls. 
- Subjects with mild or moderate hepatic impairment 




dispense routine monitoring. Also, they may have less interactions with food and drugs 
compared to VKAs[40]. Several studies, randomised trials and indirect comparisons, were 
then conducted to prove NOACs efficacy and safety, and all of them showed to be non-
inferior or even superior in terms of efficacy for stroke prevention and presented lower rates 
of intracranial bleeding with respect to warfarin[19–22, 41]. But none actually compares NOACs 
against each other, excluding, the majority of them, patients with hepatic impairment. 
 
 
Table 2 – Comparing the impact of VKA in stroke and bleeding risk in patients with hepatic impairment 
 
Seung-Jun Lee[28] and his team published a cohort analysis with 321 patients with atrial 
fibrillation and chronic hepatic disease (CTP A n= 215, CTP B or C n= 106) and concluded 
VKA therapy reduced the risk in early stage liver cirrhosis patients without increasing the 
risk of major bleeding. But, in patients with advanced liver cirrhosis, the difference in stroke 
risk was not significant and the risk of major bleeding events increased (Table 2). These 
results reveal the importance of liver disease severity as a risk factor when choosing to 
implement VKA. 
As described before, hepatic impairment can alter the anticoagulants’ effect, among 
other reasons, due to coagulopathy, to altered metabolisation of drugs and for altered 
bioavailability, a consequence of the decreased levels of albumin, affecting essentially 
molecules with high binding properties [43]. Since anticoagulants undergo hepatobiliary 
metabolism, they should be used with caution, with regular follow-up and frequent 
laboratory monitoring, until more data are available on their safety in patients with liver 
dysfunction. 
In relation to esophageal varices, they contribute to increment the risk of gastrointestinal 
bleeding, whose presence in patients taking anticoagulant therapy can be considered 
STUDY NAME POPULATION INTERVENTION CONTROL 
End Points 
Efficacy Safety 
Seung-Jun Lee  
et al 321 patients with 
cirrhosis and AF 
(mean CHA2DS2-
VASc VKA group 2.6 
± 1.8; no VKA goup 
2.2 ± 1.5) 
VKA (CTP A 
n=108 + CTP B or 
C n=65)  
No VKA (CTP 
A n=107, CTP 
B or C n= 41) 
 VKA 1.8% 
No VKA 4.7% 
VKA: CTPA 
5.62%, CTP B 
or C 18.03% 
(mean 9.61);  
 No VKA: CTP 
A 5.20%, CTP 
B or C 9.15% 
Efficacy end point: Ischaemic stroke events 
Safety end point: Major bleeding events 
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dangerous[28], which motivated their exclusion from trials evaluating NOACs in AF patients. 
A study evaluated the use of traditional anticoagulants in 136 patients with portal 
hypertension and esophageal varices and from them 84 received anticoagulant therapy. No 
relation was found between the use of OAC and bleeding risk, if there was being applied 
treatment to manage varices[29], which could be with the use of non-selective b-blockers or 
endoscopic ligation[30], and also avoidance of anti-inflammatory drugs and estrogens. It was 
concluded that it was the varices size that played a major role on bleeding risk. Condat et al. 
actually propose that the prevention of thrombosis in the venous system and its effect in not 
raising portal pressure may be an important key player in bleeding risk reduction[29]. To note 
that these findings weren’t validated in NOACs.  
Instead of large prospective trials, some of the available data on the effect of hepatic 
impairment on oral anticoagulants and their safety and efficacy on stroke prophylaxis are 
from small clinical retrospective trials and in vitro studies, which have limited relevance. It 
has been proposed from an in vitro trial, with a thrombin generation assay being used to 
assess anticoagulation potency, that the direct inhibitor of thrombin, Dabigatran, has 
increased anticoagulant effect in patients with severe hepatic impairment[9]. The reduction 
in thrombin generation reflects the level of liver disease. These data suggest that dabigatran, 
in standard dosing regimens, may lead to higher than desired anticoagulant effect in all types 
of cirrhosis patients. This finding, however, has not been established in clinical studies, in 
vivo. In a protocol[34] with a single dose administration of Dabigatran in healthy controls vs 
patients with CTP B (n=12) no differences were observed in coagulation markers or drug 
exposure[34], between groups. One of the described secondary effects of dabigatran is 
dyspepsia, probably due to the tartaric acid present in the dabigatran etexilate capsules[44], 
but it’s use with a proton-pump inhibitor compromises it’s absorption and efficacy. Also, if 
we consider the findings from the RELY trial[22], it were described higher rates of 
gastrointestinal bleeding comparing to warfarin, raising a question when it comes to patients 
with chronic liver disease and oesophageal varices, a topic requiring further attention. 
Finally, simultaneous administration with P-glycoprotein inhibitors and inducers should be 
carefully analysed, because dabigatran is a P-glycoprotein substrate[14].  
Rivaroxaban is a factor Xa inhibitor, metabolized via the CYP450 system, and a 
substrate of P-glycoprotein[14]. It is administered in a single daily dose, which could help to 
improve patient’s compliance. In rivaroxaban’s in vitro testing[9, 32], the effect of 
anticoagulation was showed to be decreased in patients with severe hepatic impairment (CTP 
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C), and no difference was described between patients with CTP A or B versus controls. 
Kubitza et al.[33] tested the effect of a single 10mg dose of rivaroxaban in patients with mild 
(n=8, CTP A) and moderate (n=8, CTP B) hepatic impairment, observing a moderate 
increase in the levels of drug exposure and prolongation of PT in patients with moderate 
hepatic impairment; the clearance was reduced and also the levels of FXa activity. Maybe 
for this reason, the use of rivaroxaban is not recommended in patients with CTP B or C (not 
included in the study) cirrhosis or in any patient with hepatic disease associated with a 
coagulopathy. The patients with mild hepatic impairment had minimal impact and no major 
adverse events occurred during the trial. The first and largest clinical study comparing the 
use of NOAC (n=20) in cirrhosis patients with a comparison cohort of patients taking 
traditional anticoagulants (n=19) is from Intagliata M. et al and lasted for 3 years. There 
were 6 patients with atrial fibrillation and the study concluded that the rate of total 
documented bleeding events was similar between the two groups (4 in the NOAC group and 
3 in the traditional therapy group) and also the rate of major bleeding (1 in the NOAC group 
– patient on rivaroxaban – and 2 in the traditional therapy group)[45]. Patients with CTP C 
were excluded. 
Apixaban, also an inhibitor of factor Xa, has the highest percentage of hepatobiliary 
metabolism of all NOACs, requiring more caution in the setting of advanced hepatic failure. 
Careful monitoring of drug levels can be accessed by anti-Xa testing[27]. Apixaban is also 
metabolized via the CYP450 system, leading to certain drug interactions and, like the other 
factor Xa inhibitors, apixaban is a substrate of P-glycoprotein. The in vitro observation 
showed a decrease in anticoagulant potency in patients with moderate or advanced cirrhosis 
– CTP B or CTP C [32]. C.E. Frost et al. tested the effect of a single 5mg dose of apixaban in 
patients with mild or moderate hepatic impairment, and no relevant changes were observed 
between groups[35] suggesting apixaban has a predictable profile and no dose adjustments 
are required in patients with mild or moderate hepatic impairment. In the already mentioned 
clinical trial, from Intagliata et al. 9 patients received apixaban and the anticoagulant effect 
remained practically unchanged in patients with CTP A or CTP B, compared to patients 
receiving traditional anticoagulation[45].  
 Edoxaban is the most recent factor Xa inhibitor and is applied once daily. It is 
metabolized via hydrolysis and it’s free from interactions with the CYP450 system, but 
interactions with P-glycoprotein (P-gp) inhibitors exist, which motivated an indication to 
reduce dosage to half when there is concomitant use of verapamil, an antiarrhythmic agent 
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and potent P-glycoprotein inhibitor[26].  A study examining the effect of a single dose 15mg 
of edoxaban in patients with CTP A (n=8) and B (n=8) found no difference in drug exposure 
between groups and the pharmacokinetics and pharmacodynamics were similar compared to 
healthy subjects[36]. Again, knowledge of drug metabolism and effects in patients with 
hepatic impairment is very limited.  
 
Table 3 – Results from studies comparing the use of traditional anticoagulation and NOACs. 
A retrospective cohort[46] from a sample of 45 patients with mild or moderate hepatic 
impairment (CTP class A and B), in which 24 had atrial fibrillation, evaluated safety and 
efficacy of traditional OAC therapy (warfarin n=15, LMWH n= 3) versus NOACs 
(rivaroxaban n=17, apixaban n= 10) during a period of 3years. 18 Patients received 
traditional therapy (9 had AF) and 27 received a NOAC (15 had AF). 10 patients had a 
bleeding event on traditional therapy and 8 on NOACs. From the traditional therapy group, 
5 where major bleeding and 3 where intracranial bleedings and 1 major bleeding was 
associated with NOAC with no intracranial bleeding described. These results may suggest 
NOACs have a safer profile. During follow-up there were no ischaemic strokes. From this 
study is missing the information on average CHA2DS2VASc score and HAS-BLED.  
Considering drug interactions with the oral anticoagulants, the VKAs have the biggest 
number of cases, but NOACs have some interactions too. Like mentioned above, they are 
substrates of the p-glycoprotein transport system (P-gp), meaning their plasma concentration 
will be affected by both inhibitors and inducers of P-gp. There are several drugs which are 
substrates of the P-gp pathway (eg. verapamil, amiodarone), that are commonly used in AF 
patients, requiring caution when administering them concomitantly[47]. Other interactions are 
STUDY NAME POPULATION INTERVENTION CONTROL 
End Points 
Efficacy Safety 
Justine Hum et al 
45 Patients with 
cirrhosis, 24 with AF 
Rrivaroxaban 20mg 
daily (n=17) 












VKA or LMWH 
5% 
N. M. Intagliata et 
al 
39 patients with 
cirrhosis (CTP A 
n=18, CTP B n=21), 
5 with AF 
Rivaroxaban 20mg 
daily (n=9) 









VKA or LMWH 
11% 
Efficacy end point: Ischaemic stroke events 
Safety end point: Major bleeding events 
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related to cytochrome P540 3A4 (eg. calcium channel blockers), one of the metabolisation 
pathways of rivaroxaban and apixaban. 
 
Table 4 - Resume of oral anticoagulants’ characteristics [9, 32–36, 40, 42, 48, 49] 
 
Reviewing, the current guidelines and approval information[50–53] do not recommend the 
use of any of the anticoagulants in patients with severe hepatic impairment (CTP C) and in 
those with associated coagulopathy and clinically relevant bleeding risk. In warfarin’s case, 
it’s use is recommended with caution and according to the INR value. For the NOAC, no 
restrictions are imposed on their use in patients with mild hepatic disease (CTP A). 
According to the approved prescribing information, apixaban requires no dose adjustments 
in patients with CTP A cirrhosis, but no specific recommendations exist for patients with 
CTP B. However, the use of apixaban must always be prudent because it has higher hepatic 
metabolism than the rest of the NOACs and it’s use is not recommended if the levels of the 
ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION 





Inhibits factor IIa Inhibits factor Xa Inhibits factor Xa Inhibits factor Xa 
t 1/2 24-58h 12-17h 5-9h 12h 10-14h 
Elimination 
92% renal, 8% 
gastro-intestinal 
80% kidneys; 20% 
gastro-intestinal 
66% kidneys ; 34% 
gastro-intestinal 
27% kidneys ; 73% 
gastro-intestinal 
50% kidneys; 50% 
gastro-intestinal 
Onset of action 3 – 5 d 2h 2 – 4 h 3 h 1 – 2 h 
Regular dose 
According to  
INR 
75 or 150 mg 
2x/d 
10 or 20 mg /d 2,5 or 5 mg 2x/d 
15 or 30 or 













according to  INR 
Safe in CTP A/B 
without adjustments. 
Attention when liver 
enzimes are altered. 
Apparently safe 
for CTP A. 
Contraindicated 
for CTP B/C 
Safe in CTP A, 
without adjustments. 
Apparently safe for 
CTP B/C. Attention 
when liver enzimes 
are altered 


















inhibitors of both 
CYP3A4 and P-
gp 
Strong inducers or 
inhibitors of both 







thrombin time test 
anti-FXa assay anti-FXa assay anti-FXa assay 
PCC: Factor IV prothrombin complex concentrate 
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hepatic enzymes, AST and ALT, are twice the upper limit of normal or in patients with CTP 
C cirrhosis. Dabigatran too is not recommended in patients with elevated liver enzymes and 
it’s use is apparently safe in patients with moderate hepatic impairment. Rivaroxaban is not 
recommended in patients with moderate or severe hepatic impairment (CTP B and CTP C) 
or in any degree if associated with coagulopathy; no dosage recommendations are 
established for patients with CTP A cirrhosis. Edoxaban, similarly is not recommended in 
patients with moderate or severe hepatic impairment (CTP B and CTP C). Further, according 
to the ESC 2016 guidelines, warfarin receives a level IA recommendation and dabigatran, 
rivaroxaban and apixaban a level IB, these ones recommend for patients with difficulties to 
maintain a therapeutic INR with warfarin.  
Overall, no dose adaptations are recommended for any of the mentioned agents when 
used in patients with CHD, reflecting the insufficient data and the limited clinical experience 
in these patients. The only studies concerning the effect of NOACs in patients with chronic 
hepatic disease were performed in vitro or on a single dose basis.  
 
Reversal agents for the Oral anticoagulants  
For many physicians, the lack of an agent to reverse the novel oral anticoagulants effect 
may cause discomfort when deciding to administrate them. Even though safety studies in 
NOAcs are reassuring, the management of a serious bleeding event remains a challenge. 
While physicians have a vast experience with warfarin’s use, there is still big concern about 
NOACs and the lack of widely available antidotes. The prothrombin complex concentrates 
(PCC) and activated PCC, recombinant factor VII were being used as reversal agents before 
new agents came along[54]. Recently the FDA and the EU approved the use of Idarucizumab, 
an antibody fragment that binds to dabigatran with an affinity 350 times higher than observed 
with thrombin, which proved to have a rapid and complete reverse response[55] even under 
urgent circumstances. Adexanet alfa was also approved by the FDA[56], very recently on May 
2018, and Ciparatang another more “universal” reversal agent, is still under study but it’s 







Left atrial appendage ligation and closure 
 
Table 5 – Implantation devices and study results from populations with contraindications to OAC 
 
In patients with non-valvular AF, thrombus formation his mostly taking place at the left 
atrial appendage (LAA)[64], partly related to its morphology[67]. Considering the limitations 
described to OACs use, alternative methods were studied and developed as local therapies. 
The left atrial appendage occlusion and excision or ligation are promising alternatives, 
available for patients with contraindication to OAC therapy, providing the desired 
cardioembolic protection and removing the need for long-term OAC therapy. The 2016 






















Boersma et al.[57] 
Watchman 1 year 4.5 2.3 98.5 2.8 1.1 2.6 
Dual or single 
antiplatelet therapy for 
6 months and OAC 
Reddy et al.[58] 
Watchman 1.2 year 4.4 NR 94.7 8.7 2.3 NR 
Dual antiplatelet 
therapy 6 months 
and lifelong aspirin 




4.5 3.1 97.3 4.9 2.3 2.1 
Single or double 
antiplatelet therapy 1-3 
months followed by single 
antiplatelet therapy other 
3 months minimum. 
Urena et al.[60] 
Amplatzer 
20 ± 5 
months 
5 4 98.1 5.8 1.1 1.9 
Single or double 
antiplatelet therapy for 
1-3 months, followed 




Amplatzer 9 months 5 3 100 7.3 2.2 1.1 
Dual antiplatelet 
therapy for 6 months 
and lifelong single 
antiplatelet therapy 
Minguez et 
al.[62] Amplatzer 2 years 4 3 94.6 5.4 2.4 3.1 
Clopidogrel 3-6 
months and aspirin 
until 6-12 months 




4.3 3.4 100 3.6 2.2 1.1 
3 months dual 
antiplatelet therapy 
followed by single 
therapy 
Seeger et al.[64] 
Amplatzer 
Watchman 
1.1 years 4.4 4.2 NR 3 2% NR 
3-6 months dual 
antiplatelet therapy 
followed by long-term 
therapy with aspirin. 
Price et al.[65] 
Lariat 112 days 4.1 3.2 94% 9.7% 1.3 NR 
Single or double 
antiplatelet therapy 




Lariat 1 month 3.9 3.4 98% 10.1 to 2.2* NR NR 
Single antiplatelet 
therapy  
PPT: post-procedure therapy more frequently  applied  
NR: not reported 
*rate changed according to the needle used during procedure 
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European guidelines and the 2014 American Heart Association/American Stroke 
Association guidelines for Stroke and TIA gave a class IIb recommendation, level of 
evidence B for percutaneous LAAC in patients unsuitable for OAC[4]. 
There are different techniques presently accessible in clinical practice. Surgical left 
atrial appendage closure is being performed since 1940 and is still currently used during 
cardiac surgery, for other motives than atrial fibrillation, by suture, staples or clips[68]. The 
LAA ligation, however, might be incomplete and these patients will continue at risk for 
thrombus formation, if not at a greater risk[69]. Also, not all thromboembolic events derive 
from the LAA and there’s still at risk of thromboembolic events derived from the aorta and 
from carotid atherosclerosis[48]. 
Besides that technique, other new and less invasive options exist nowadays. They are 
non-surgical, minimally invasive catheter-based interventions that consist in the introduction 
of a device and it’s placement at the LAA.  PLATOO was the first system designed to 
perform endocardial LAA occlusion on the market and, although it showed promising 
results, even in patients not eligible for anticoagulant therapy[70, 71] [72], it was removed from 
the market in 2006. 
The WATCHMAN device came next. It started being implanted in 2002, and consists 
of a permanent self-expandable implant, permeable to blood and, for this reason, its 
manufacturer recommends the use of thromboprophylatic drugs until endothelialisation is 
complete. Therefore, during the periprocedure period and for a variable period after, the risk 
of bleeding events will be increased. The absence of residual flow in the LAA defines the 
success of the implantation. Several studies were conducted on the safety and efficacy of 
this approach. The PROTECT AF [73] study was a non-inferiority randomised control trial 
(RCT), involving 707 patients with non-valvular atrial fibrillation, randomly assigned to 
device implantation and temporary post-implant OAC therapy and lifelong aspirin, or to 
long-term warfarin therapy, in a 2:1 ratio (463 / 244). The 3.8 years follow-up analysis, 
proved this technique was not only non-inferior to warfarin but also superior, when 
considering combined outcomes of all strokes, systemic embolism, cardiovascular death and 
all-cause mortality[74]. Later, the PREVAIL trial revealed an improvement on procedural 
safety but the non-inferiority criteria were not achieved. The major complications related to 
this approach are described, and consist mostly of pericardial effusion, with tamponade, 
procedure air embolism and acute stroke and the events rate seems to be related to the 
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operator experience, decreasing when this increases[73]. In both of these RCT, the patient’s 
inclusion criteria did not included subjects with hepatic impairment. Still and all, we consider 
that describing the data available on these approaches in populations with contraindications 
to anticoagulant therapies can be revealing, allowing to make some previsions for the cases 
where chronic hepatic disease is an issue. 
More recently, the Ewolution[57, 75] registry included 1021 patients at high risk of stroke 
and moderate-to-high risk of bleeding, which they considered to be representative of a real-
world population. From them, 73% of patients were unsuitable for OAC therapy (the criteria 
are not described) and 4.3% had hepatic impairment. After implantation, anticoagulants were 
recommended for 3-6 months, so that 27% stayed with OAC, 59% with dual anti-platelet 
therapy, 8% on single antiplatelet therapy and only 6% without any type of OAC. In this 
study, 98.5% of the patients were successfully implanted (absent or minimum residual flow 
in 99.7%). Importantly, the incidence of periprocedure complications did not differ between 
subjects on OAC vs. not on OAC therapy after implantation, but was significantly lower in 
patients previously considered ineligible for OAC compared with eligible patients. Finally, 
for those with high risk of bleeding (HAS-BLED >3), the events rate was superior. The 
results from the 2-year follow-up were not released yet, but we can already appreciate that 
this device has a good sealing success and seems to be safe and effective in stroke risk 
reduction (At 1 year follow-up, 73% of patients weren’t taking any oral anticoagulant and 
1.1% had a stroke).  
The ASAP trial [58] analysed the safety and the efficacy of LAA closure with the 
Watchman device in a group of 150 patients who had contraindication to warfarin therapy, 
mostly related to bleeding tendencies, but who were eligible to antiplatelet therapy; none had 
chronic hepatic disease. After device implantation, with a success rate of 94.7%, patients 
received antiplatelet therapy with clopidogrel or ticlopidine for 6 months and lifelong 
aspirin. The device showed to be safe and effective without the need for warfarin therapy in 
the post-implant period. The procedure and device related events occurred in 8.7% of the 
patients and the annual rate of all cause stroke observed was 2.3% (1.7% ischaemic stroke, 
0.6% haemorrhagic stroke). 
The other device available for LAA closure is the Amplatzer Cardiac Plug, a self-
expanding double-disc nitinol frame covered with a polyester patch that was primarily 
developed for closure of atrial septal defects. A report from 2011 described, retrospectively, 
the initial European experience[76] on this device during the first 24h, involving 143 patients, 
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with an implantation success of 96% and a periprocedure complications rate of 7%. This 
patients were kept on heparin during procedure and continued DAPT for 1-3 months and 5 
more months on aspirin alone. Then, a multicentre registry from 22 sites in Europe, including 
1053 patients, reported a procedural success rate of 97.3%, an annual rate of systemic 
embolism of 2.3%, and a complications rate of 4.9%[59]. They verified patients who were 
under more intense antithrombotic therapy had more major bleeding events, and also that 
patients taking no therapy rather than aspirin after procedure were at higher risk for 
ischaemic events (TIA and stroke).  
Several registries followed, with smaller populations, like the Iberian registry[62], with 
the involvement of 167 patients, reporting an implant success of 94.6% and a periprocedure 
event rate of 5.4%. An Italian single center registry[63] described an implant success of 100% 
and a complications rate of 3.6% and a Canadian single center registry[60] described a 98.1% 
success of implantation and a complications rate of 4.9%; patients underwent LAA closure 
with Amplatzer device and received 1 to 3 months DAPT and then single platelet therapy[60]. 
Other single center registry from the University of Kiel[61] reported an implantation rate of 
100% and a periprocedure events rate of 7.3%. A registry from the Cardiology department 
of the University of Ulm[64], involving 101 patients with non-valvular AF who were 
unsuitable to take oral anticoagulant therapy, assigned patients to Watchman (n=38) implant 
or to the Amplatzer device (n=63), based on morphology of LAA; patients then received 
double antiplatelet therapy for 3 or 6 months after implant. The results showed no difference 
between the two devices for the main efficacy outcome (2%) groups or for the fact that 
patients were prescribed with DAPT for 3 or 6 months. For the bleeding events rate, it was 
lower with 3 months on DAPT compared to 6 months[64]. 
Then, another approach started to be carried out more recently, the percutaneous 
epicardial LAA occlusion and several devices are now under development[48]. Among them, 
the Lariat suture device, introduced via femoral and with epicardial access via catheter, was 
already approved in the EU and was tested in a RCT for preclinical data to test its feasibility 
in humans[77]. Matthew J. Price et al.[65] conducted an investigation about the safety and 
efficacy of this technique in 154 patients from 8 centres in the US, with the primary end 
point defined as implantation success, which was achieved in 94% of the cases, and had 10% 
major procedure complications, the majority from major bleeding events. The average time 
of follow-up were 112 days, and from the 134 with possible follow-up, 2 had a stroke, 
causing the death to one of them. The biggest advantage of this technique is that it doesn’t 
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leave any instrument behind, which would require anticoagulation until endothelialisation 
was complete, and also the fact that size and the morphology of the auriculae don’t influence 
the approach. The major complications of the Lariat technique are cardiac perforation related 
to the epicardial access and pericardial effusion. A more recent registry[66], with data from 
18 centres in the US, involving 721 patients, declared an implant success rate of 98%. Then 
they realized the periprocedure complications ate was different according to the needle used 
for pericardial access, varying from 10,1% with the large-bore needle to 2,2% with the 
micro-puncture one. In both cases, no homogeneous post-procedure protocol was followed, 
varying from anticoagulated states to double antiplatelet therapy to no agent at all. 
The main advantage of the LAAC procedure is making long-term OAC therapy 
unnecessary, and it should be considered in patients with both high risk of stroke and 
haemorrhage. These techniques are not recommend in low risk cases because of the 
complications experienced during the periprocedure period, with higher rates than the 
thombo-embolic risk, camouflaging the net clinical benefit of these options. Moreover, their 
efficacy and superiority over oral anticoagulant therapy, in patients with contraindications 
to OAC, is not entirely established yet. From these studies, only one RCT and two cohorts 
enrolled patients with known hepatic impairment. EWOLUTION enrolled 1021 patients and 
4.2% of them had liver impairment; Urena et al. involved 52 patients and 3,8% had liver 




















5 | Discussion  
 
There is a considered amount of patients with atrial fibrillation and at high risk for 
stroke, who require thromboprophylatic treatment, with a well-established net benefit, but 
who also present high risk for bleeding, not only derived from oral anticoagulant therapy 
intake but also from other comorbidities, like chronic hepatic disease. For these patients, the 
best approach is unclear, raising the question of exactly which patients will benefit from 
which type of therapy, pharmacological or not.  
For a long time, oral anticoagulant therapy has been the gold standard therapy for stroke 
prophylaxis in patients with AF, and warfarin assumed the main role. With the rise of the 
new anticoagulants, studies were conducted to establish their safety and efficacy, and all of 
them proved to be superior compared to warfarin in the primary efficacy outcome[19–22], also 
a reflex of a reduction on intracranial haemorrhage events. However, these conclusions were 
established in populations without liver impairment. Withal, the novel oral anticoagulants 
presented wider gastrointestinal effects than warfarin, except for Apixaban[78], and this 
observation has an enhanced importance in cirrhotic patients who might present with 
esophageal varices, a major risk factor for gastrointestinal bleeding.  
At the moment, no large, well-powered, prospective trial exists examining the safety of 
any therapeutic anticoagulant agent in cirrhosis patients, but considering the available 
information, we can already highlight the importance of “drawing” a personalised treatment 
for each patient. It’s essential to take the patient’s risk profile into account, employing variate 
scores and to access also the level of hepatic impairment and notice if esophageal varices or 
thrombocytopenia are present.  
However, these risk-stratification algorithms derive originally from clinical-trial cohorts 
with careful patient selection and close monitoring, not necessarily reflecting real-world 
situations. In fact, many patients at high risk for bleeding were excluded from these 
studies[23]. They were not build to be used in patients with chronic hepatic disease and the 
quality of their information might be inaccurate. The HAS-BLED score, unlike the 
CHA2DS2VASc, has a risk criteria for major bleeding in patients with abnormal liver 
function and with atrial fibrillation under anticoagulant therapy, considering the eventual 
thrombocytopenia, splenomegaly or prolonged international normalized ratio (INR), which 
coexist with haemorrhagic diathesis[24].  
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Another issue is related to the monitoring tests available in clinical practice. The 
coagulation tests: aPTT (activated partial thromboplastin time) and PT (prothrombin time) 
are used to estimate the risk of bleeding, and treatment with warfarin is monitored with INR 
(international normalized ratio), based on PT level. However, these results are poorly 
correlated with the bleeding tendencies, has they are designed to assess isolated defects of 
pro-coagulants, but are insensitive for anticoagulant factors[11]. Nowadays the anti-FXa 
assayis the current recommended procedure to monitor the direct factor Xa inhibitors levels 
and, for the thrombin inhibitor, the modified thrombin time test is an available option[26, 27]. 
Additionally, physicians make a subjective evaluation, identifying risk factors outside 
of the scales and different weights might be attributed to different factors. Also, the 
intervention in modifiable risk factors can have a major role in prevention of ischaemic and 
bleeding events (hypertension, management of OAC therapy, co-medication with 
antiplatelet or NSAID, alcohol intake, etc)[4, 25] and are specially the patients with a “special” 
risk profile that demand the biggest attention, due to the multiple morbidities and varied 
medication.  
For all these reasons, the different treatment options should be evaluated, presented and 
discussed to and with the patients, in order to provide the best care according to the patient’s 
expectancies, explaining the possibilities and the limitations of the different approaches 
available [Figure 1]. This consultation gives the patient a chance to make an informed 
decision about its treatment, which usually helps with therapy adherence issues. 
Interestingly, the benefits associated to OAC therapy in patients affected by both AF 
and CHD go beyond stroke prophylaxis. They are also recommended for portal vein 
thrombosis prevention[8, 79] and more interestingly, they proved to play an important role in 
disease modification in patients with chronic hepatic disease, by blocking fibrogenesis[80] 
through the inhibition of fibrin and factor Xa, as there is a known link between the activation 
of the coagulation cascade and the progression of liver fibrosis. Also, atrial fibrillation and 
liver disease might share pathophysiological paths, which may serve as common therapeutic 
targets[6], deserving more investigation in the near future. 
To be able to build a trustworthy guideline for physicians on the proper use of 
anticoagulation, more studies are required, pooled long-term analysis, comparing the 
NOACs among each other and enquiring why each one of the anticoagulants could be 
superior, in terms of safety and efficacy, and for which patient. Until today, the 
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pharmacological properties of all anticoagulants in cirrhotic patients are still poorly 
understood. Concerning the safety and efficacy of traditional therapies in cirrhotic patients, 
they were established for a group of selected patients, with compensated disease[28]; and in 
a small comparison between traditional anticoagulants with the two NOACs, rivaroxaban 
and apixaban, the bleeding risks were shown to be similar[45], or even lower with the novel 
agents[46]. However, this is not enough to cover all the patients admitted at the hospital. 
Regarding the NOACS, all we have on our disposal are in vitro studies[9, 32], small 
retrospective trials or registries[45, 46] with considerable variations in study design, describing 
their characteristics and proposing how hepatic impairment can affect their properties, based 
on observations after single dose administrations[33, 34, 36].  
Until now, no formal dosing adjustments or monitoring advertisements were 
recommended for cirrhotic patients, and although the most recent guidelines advise the use 
of NOACs when the patients have difficulty to maintain a stable INR, it’s also true that no 
anticoagulant is recommended in patients with severe hepatic impairment (CTP C), with 
high risk of bleeding and coagulopathy. Only dabigatran is apparently safe in patients with 
moderate hepatic impairment[34], and parallel to apixaban, their use must be prudent 
according to the levels of the liver enzymes. Both rivaroxaban and edoxaban are not 
recommended for patients with CTP B or CTP C. 
For their many characteristics, like easier monitoring and improved rates on 
haemorrhagic stroke, the novel oral anticoagulants are expected to replace VKA as the first-
line medication in stroke prophylaxis, but its safety and superiority is still not proved in 
patients with chronic hepatic disease. 
For the listed reasons, even with the different oral anticoagulant options, there is still a 
great number of patients that will continue to be poor candidates for long-term anticoagulant 
treatment. At present, LAA amputation, ligation, or occlusion provide an acceptable solution 
for some of these patients, which from the presented trials (Table 5) has an implant success 
non-inferior to 94% with stroke rates per year inferior to 2.4%. The LAAC approach counts 
with several different devices, some not available in the United States (US) but available in 
Europe (EU), like the Amplatzer plug and the Lariat system. The Watchman implant is the 
one with more robust results, approved in EU and by the FDA, in the US, which proved to 
be at least non-inferior to warfarin, in patients with[57, 58] and without contraindications to 
OAC. Indeed, long-term trials found that patients experience lower rates of major bleeding 
events after the periprocedure period, when using this device, than the ones receiving long-
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term warfarin[81]. The Watchman device is indicated[4] to reduce the risk of 
thromboembolism in patients suffering from non-valvular atrial fibrillation with increased 
risk of stroke, requiring thromboprophylatic therapy (with a  CHADS2 equal or more than 
2) but who were deemed unsuitable for warfarin, p.e because they have difficulties to follow 
up closely their INR, or experienced stroke even on anticoagulant regime. Also, they must 
have a compatible profile to beneficiate from this technique and they must be aware of the 
implications related to it. Future studies should investigate if a comorbidity of chronic 
hepatic disease affects patients’ outcomes. 
Although there is indirect comparative data proposing that LAA occlusion with the 
Watchman device is non-inferior to DOACs[82] in patients without contraindications to OAC, 
there have been no prospective randomized controlled trials to compare these two 
management options, or an OAC with any other device. The PRAGUE-17 study is a 
randomized controlled trial that will compare percutaneous LAA occlusion with either the 
Amplatzer Amulet or the Watchman device versus DOACs[83] in patients both at risk for 
stroke and bleeding, filling this gap partly. But again, these trials are not focused on 
populations with hepatic impairment.  
In consideration to the other percutaneous left atrial appendage closure strategies, it’s 
difficult to establish more conclusions given the amount and the quality of the clinical trials, 
with a mix of retrospective and prospective data, and lacking randomization. The Amplatzer 
Amulet device received a CE approval in EU for LAAC, and also showed some impressive 
results, majoritarily from small registries, and involving patients with contraindications to 
OAC. The Lariat Loop system is another device approved in EU, also evaluated in small 
trials, whose difference from the two mentioned systems consists on the implantation 
technique and purpose, being more indicated for patients without a suitable anatomy for 
endocardial LAA occlusion. It is placed via epicardial access and it’s supposed  to close the 
auricula from the inside[65]. Because it’s not a real implant and doesn’t require 
endothelisation, like the Watchman implant p.e., it might be an interesting solution to offer 
to patients unsuitable to anticoagulants, whose use in this case might be unnecessary. Also 
to point out that the the study from Lakkireddy et al. revealed how a small change in the 
protocol can improve outcome results, leaving the space to find better solutions in the future.  
About the data related to the interventional procedure complications of LAAC, they 
occur mostly in the periprocedure period and decrease in time and with operator experience, 
which is the opposite of what occurs in the control group with warfarin prescription, which 
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rate remains constant over time[73]. The periprocedure complications rate highlights the risk 
of an invasive procedure, and also sets out the importance of time for the balance risk-benefit 
of this approach. Patient selection is mandatory and the patients with very high risk of stroke 
and bleeding, with a sufficient life expectancy to profit from LAAC, are the ones considered 
to benefit the most from these techniques, avoiding long-term anticoagulation. Therefore, 
patients with many co-morbidities and limited life expectancy may not expect great benefit 
from this technique, given it’s time dependent[59]. Due to the lack of prospective trials, the 
net clinical benefit of LAAC is not established yet, especially in this particular subset of 
patients. To point out that LAAC isn’t meant to take over oral anticoagulant therapy has the 
first-line of treatment in non-valvular AF. It is rather an alternative to be proposed in cases 
where anticoagulation cannot be tolerated.  
Another important topic is the variety of protocols adopted in these studies, especially 
regarding the post-procedure therapy, making it very hard to take further conclusions about 















Figure 2 – Algorithm proposed for patients evaluation and therapeutical options 
Non-pharmacological 
therapy 
Patient with Chronic Hepatic Disease  
and Atrial Fibrillation 
CHA2DS2VASC < 2 
No therapy 
CHA2DS2VASC ≥ 2 or 




 Warfarin is the first-
line 
 DOAC if poor INR 
control 
 CTP < C for all DOAC 
 Regular monitoring 
 
  
 HAS-BLED ≥3 
 Long-term results 
 Adequate life 
expectancy  
 High periprocedure 
complications 
 Unnecessary long-term 
OAC therapy 
* according to the 2016 ESC guidelines 
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These findings suggest that investments should be made to improve the implantation 
technique and on the post-procedure protocol, developing more uniform inclusion criteria, 
including patients at both high risk for stroke and bleeding, justifying the concern to use 
OACs, in order to reduce periprocedure complication events. Eventually it should be 















6 | Conclusions 
 
Healthcare professionals have several pharmacological and non-pharmacological 
options for stroke prophylaxis, but no guidelines exist to guarantee the best treatment to 
provide to their patients. Selection must be based on the evaluation of the potential risks 
and the potential benefits of each approach.  The appropriate method depends on patient’s 
clinical factors such as tolerability to oral anticoagulants and adherence, risk for bleeding, 
comorbidities like renal insufficiency or liver impairment, concomitant medications, age 
and life expectancy, patient’s own expectancies and wishes. It is mandatory to take into 
account all these factors before choosing the best treatment to apply.  
About what’s the best option for each patient, further studies are required, aimed at 
the identification of the best method for which patient, and for that direct comparisons 
between the different methods available are crucial. Until now, it’s not possible to claim 
superiority of one NOAC agent over the other. Although NOACs offer several advantages 
over warfarin, their safety isn’t well proven yet for patients with chronic hepatic disease.  
Comparisons should be made also with the different LAAC techniques, and the 
different anticoagulant options.  
Another topic to be addressed by future clinical studies is the need for long-term or 
indefinite antithrombotic therapy after implantation of an LAA occlusion device. 
The relevance of this subject is evidenced by the growing number of older persons 
and the prevalence of multiple chronic morbidities, such as atrial fibrillation and chronic 
hepatic disease, in a part due to more sedentarism and obesity. 
In the future, it’s undeniable that more large, well-designed trials, involving the 
different devices and comparing them with the different OAC possibilities are required, 
to ensure the efficacy and safety of all these approaches and to allow further conclusions 









7 | Limitations 
 
In this review, we included different types of studies: randomized trials, cohorts, 
registries, with a mix of prospective and retrospective trials, with different populations, not 
all limited to patients with chronic liver disease, due to the insufficient studies published in 
these circumstances, which obliged a change in the inclusion criteria during the research 
process on the databases. 
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